中國玻璃(03300.HK):199.4萬股要約股份獲有效接納 要約失效
格隆匯2月10日丨信義玻璃(00868.HK)、中國玻璃(03300.HK)發佈公吿,截至2021年2月10日下午四時正,要約人已收到九份有效接納,涉及合共199.4萬股要約股份,佔本公吿日期該公司已發行股份約0.11%;及概無接納任何購股權要約。可換股債券要約已於2021年1月4日失效。接納股份連同要約人及其一致行動人士已擁有的股份,合共為2096萬股股份,佔本公吿日期該公司全部已發行股本約1.16%。
由於接納條件尚未達成,故要約並未成為無條件。要約人公佈,要約將不會獲延續或修訂。要約人進一步公佈,於2021年2月10日下午四時正,要約結束接納及失效。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.